Amylyx Pharmaceuticals, Inc. AMLX Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Amylyx Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amylyx Pharmaceuticals, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amylyx Pharmaceuticals, Inc.'s additional paid-in capital?
- Amylyx Pharmaceuticals, Inc. (AMLX) reported additional paid-in capital of $1.07B in Q1 2026.
- How has Amylyx Pharmaceuticals, Inc.'s additional paid-in capital changed year-over-year?
- Amylyx Pharmaceuticals, Inc.'s additional paid-in capital increased by 26.3% year-over-year, from $844.01M to $1.07B.
- What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s additional paid-in capital?
- Over 4 years (2021 to 2025), Amylyx Pharmaceuticals, Inc.'s additional paid-in capital has grown at a 287.9% compound annual growth rate (CAGR), from $4.67M to $1.06B.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.